Physicochemical Properties
| Molecular Formula | C??H???F?N??O? |
| Molecular Weight | 1505.77 |
| Related CAS # | Targaprimir-96;1655508-14-7 |
| Appearance | Typically exists as solid at room temperature |
| Synonyms | Targaprimir96 TFA; Targaprimir 96 TFA |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | Targaprimir-96 TFA reduces mature miR-96 levels in MDA-MB-231 triple negative breast cancer cells, demonstrating a dose-response with an IC50 of ~50 nM. Targaprimir-96 TFA (50 nM) increases the amount of pri-miRNA while decreasing the quantities of pre-miRNA and mature miRNA in a dose-dependent manner[1]. Targaprimir-96 TFA (50 nM; 48 hours) raises FOXO1 levels and induces apoptosis in the breast cancer cell line 4175.[1]. Targaprimir-96 TFA binds RNA3 (which contains both the Drosha site and the neighboring 1×1 nt GG internal loop) at a Kd of 85 nM. Targaprimir-96 binds to RNA1, RNA2, RNA4, and RNA5 at Kd values of 1.2, 0.9, 1.2, and 1.5 μM. Targaprimir-96 TFA is extremely RNA-selective, recognizing both the 1×1 nt GG and 1×1 nt UU loops with high affinity, efficiently discriminating against a number of related targets [1]. |
| ln Vivo | In a mouse model of triple-negative breast cancer (TNBC), tartaprimir-96 TFA (10 mg/kg; ip; every other day for 21 days) reduces tumor growth[1]. In FVB/n mice, the plasma peak concentration of Targaprimir-96 (2 or 7 mg/kg; ip) is around 4 hours. Notably, even 48 hours after injection, the amount of Targaprimir-96 TFA still in plasma (1.6 μM for the 2 mg/kg dosage and 1.9 μM for the 7 mg/kg dosage) is significantly higher than the 50 nM cellular concentration that caused apoptosis[1]. |
| Animal Protocol |
Animal/Disease Models: Female NOD/SCID (severe combined immunodeficient) mouse (Mouse Model of TNBC)[1] Doses: 10 mg/kg Route of Administration: ip; every other day for 21 days Experimental Results: diminished levels of mature miR-96 by ∼50% and increased levels of pri-miR-96, with a concomitant increase of FOXO1. No toxicity was observed. |
| References | [1]. Velagapudi SP, et al. Design of a small molecule against an oncogenic noncoding RNA. Proc Natl Acad Sci U S A. 2016 May 24;113(21):5898-903. |
Solubility Data
| Solubility (In Vitro) | May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples |
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.6641 mL | 3.3206 mL | 6.6411 mL | |
| 5 mM | 0.1328 mL | 0.6641 mL | 1.3282 mL | |
| 10 mM | 0.0664 mL | 0.3321 mL | 0.6641 mL |